KR20160085817A - 동종항체 유도 만성 이식편대숙주병의 치료 및 예방 방법 - Google Patents

동종항체 유도 만성 이식편대숙주병의 치료 및 예방 방법 Download PDF

Info

Publication number
KR20160085817A
KR20160085817A KR1020167015178A KR20167015178A KR20160085817A KR 20160085817 A KR20160085817 A KR 20160085817A KR 1020167015178 A KR1020167015178 A KR 1020167015178A KR 20167015178 A KR20167015178 A KR 20167015178A KR 20160085817 A KR20160085817 A KR 20160085817A
Authority
KR
South Korea
Prior art keywords
substituted
cgvhd
unsubstituted
inhibitor
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020167015178A
Other languages
English (en)
Korean (ko)
Inventor
브루스 알 블레이자
라이언 플린
Original Assignee
파마싸이클릭스 엘엘씨
리전츠 오브 더 유니버스티 오브 미네소타
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파마싸이클릭스 엘엘씨, 리전츠 오브 더 유니버스티 오브 미네소타 filed Critical 파마싸이클릭스 엘엘씨
Priority to KR1020237021643A priority Critical patent/KR20230104754A9/ko
Publication of KR20160085817A publication Critical patent/KR20160085817A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
KR1020167015178A 2013-12-02 2014-12-02 동종항체 유도 만성 이식편대숙주병의 치료 및 예방 방법 Abandoned KR20160085817A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237021643A KR20230104754A9 (ko) 2013-12-02 2014-12-02 동종항체 유도 만성 이식편대숙주병의 치료 및 예방 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361910944P 2013-12-02 2013-12-02
US61/910,944 2013-12-02
US201461973178P 2014-03-31 2014-03-31
US61/973,178 2014-03-31
PCT/US2014/068177 WO2015084857A1 (en) 2013-12-02 2014-12-02 Methods of treating and preventing alloantibody driven chronic graft versus host disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237021643A Division KR20230104754A9 (ko) 2013-12-02 2014-12-02 동종항체 유도 만성 이식편대숙주병의 치료 및 예방 방법

Publications (1)

Publication Number Publication Date
KR20160085817A true KR20160085817A (ko) 2016-07-18

Family

ID=53270044

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167015178A Abandoned KR20160085817A (ko) 2013-12-02 2014-12-02 동종항체 유도 만성 이식편대숙주병의 치료 및 예방 방법
KR1020237021643A Pending KR20230104754A9 (ko) 2013-12-02 2014-12-02 동종항체 유도 만성 이식편대숙주병의 치료 및 예방 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237021643A Pending KR20230104754A9 (ko) 2013-12-02 2014-12-02 동종항체 유도 만성 이식편대숙주병의 치료 및 예방 방법

Country Status (14)

Country Link
US (6) US20150157634A1 (enExample)
EP (1) EP3076975A4 (enExample)
JP (5) JP2017501140A (enExample)
KR (2) KR20160085817A (enExample)
CN (2) CN110478353B (enExample)
AU (4) AU2014360758B2 (enExample)
BR (1) BR112016012158A2 (enExample)
CA (2) CA2932255C (enExample)
EA (1) EA201691020A1 (enExample)
IL (4) IL292522A (enExample)
MX (2) MX389020B (enExample)
PH (2) PH12020552048A1 (enExample)
TW (3) TWI743019B (enExample)
WO (1) WO2015084857A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250151610A (ko) 2012-06-04 2025-10-21 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
CA2928721C (en) * 2013-10-25 2020-12-22 Pharmacyclics Llc Use of ibrutinib for treating and preventing chronic graft versus host disease
AR102871A1 (es) 2014-12-03 2017-03-29 Pharmacyclics Llc Métodos de tratamiento de fibrosis
ES2863700T3 (es) 2016-03-22 2021-10-11 Mayo Found Medical Education & Res Uso de inhibidores de ácido graso sintasa para tratar la fibrosis
WO2018002958A1 (en) * 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
US20200054721A1 (en) * 2016-10-21 2020-02-20 Bruce R. Blazar Materials and methods for treating or preventing graft-versus-host-disease
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
WO2021038540A1 (en) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
US12496303B2 (en) 2020-10-19 2025-12-16 Washington University Conditioning agents for use in allogeneic hematopoietic stem cell transplantation
US20240025990A1 (en) * 2020-12-01 2024-01-25 City Of Hope Prevention and treatment of graft-versus-host disease (gvhd)
EP4284434A4 (en) * 2021-01-30 2024-12-25 BeiGene Switzerland GmbH METHODS FOR TREATING CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION USING BTK INHIBITORS
US20240287781A1 (en) 2023-02-28 2024-08-29 Toto Ltd. Wall-mounted flush toilet

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US20060182723A1 (en) * 2005-01-25 2006-08-17 Spellberg Brad J Methods for treating refractory infections in neutropenic individuals
US7625880B2 (en) * 2006-01-13 2009-12-01 Pharmacyclics, Inc. Inhibitors of tyrosine kinases and uses thereof
DK2529622T3 (en) * 2006-09-22 2018-05-07 Pharmacyclics Llc INHIBITORS OF BRUTON-TYROSINKINASE
US20110224235A1 (en) * 2008-07-16 2011-09-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
US8765754B2 (en) * 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
AU2010286351A1 (en) * 2009-08-31 2012-03-15 Amplimmune, Inc. B7-H4 fusion proteins and methods of use thereof
US20120071497A1 (en) * 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
KR101580714B1 (ko) * 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도
KR20140058543A (ko) * 2011-07-08 2014-05-14 노파르티스 아게 신규 피롤로 피리미딘 유도체
US9522917B2 (en) * 2012-04-11 2016-12-20 Acerta Pharma B.V. Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
JP6257600B2 (ja) * 2012-05-25 2018-01-10 スローン ケタリング インスティテュート フォア キャンサー リサーチ Ｇｉ症候群及び移植片対宿主病の治療方法
WO2014127200A1 (en) * 2013-02-15 2014-08-21 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
CA2928721C (en) * 2013-10-25 2020-12-22 Pharmacyclics Llc Use of ibrutinib for treating and preventing chronic graft versus host disease
IL315294A (en) * 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor

Also Published As

Publication number Publication date
IL292522A (en) 2022-06-01
PH12016501051A1 (en) 2016-08-15
PH12020552048A1 (en) 2022-05-11
AU2014360758B2 (en) 2020-03-26
KR20230104754A9 (ko) 2024-11-15
AU2022203810B2 (en) 2024-10-03
AU2020204276A1 (en) 2020-07-16
IL245715A0 (en) 2016-07-31
EP3076975A4 (en) 2017-05-03
WO2015084857A1 (en) 2015-06-11
MX389020B (es) 2025-03-20
JP2017501140A (ja) 2017-01-12
JP2025118595A (ja) 2025-08-13
TWI743019B (zh) 2021-10-21
AU2022203810A1 (en) 2022-06-23
CN110478353A (zh) 2019-11-22
JP2023029899A (ja) 2023-03-07
US20250381188A1 (en) 2025-12-18
JP2020105181A (ja) 2020-07-09
JP2024072291A (ja) 2024-05-27
TW202402295A (zh) 2024-01-16
CA2932255C (en) 2023-10-10
IL276683A (en) 2020-09-30
CN110478353B (zh) 2022-12-30
US20180078558A1 (en) 2018-03-22
CN105939717B (zh) 2019-09-13
US20230100137A1 (en) 2023-03-30
AU2024278490A1 (en) 2025-01-09
CN105939717A (zh) 2016-09-14
TW201605454A (zh) 2016-02-16
TW202228700A (zh) 2022-08-01
EP3076975A1 (en) 2016-10-12
IL315228A (en) 2024-10-01
MX2022000209A (es) 2022-02-03
CA2932255A1 (en) 2015-06-11
US20210177854A1 (en) 2021-06-17
MX2016006955A (es) 2016-09-07
CA3210338A1 (en) 2015-06-11
BR112016012158A2 (pt) 2017-09-26
AU2014360758A1 (en) 2016-06-16
US20150157634A1 (en) 2015-06-11
US20240293409A1 (en) 2024-09-05
KR20230104754A (ko) 2023-07-10
EA201691020A1 (ru) 2017-01-30

Similar Documents

Publication Publication Date Title
US20240293409A1 (en) Methods of treating and preventing alloantibody driven chronic graft versus host disease
AU2022202686B2 (en) Methods of treating and preventing graft versus host disease
HK40086449A (en) Methods of treating and preventing graft versus host disease
EA045869B1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PC1904 Unpaid initial registration fee

St.27 status event code: A-2-2-U10-U14-oth-PC1904

St.27 status event code: N-2-6-B10-B12-nap-PC1904